etoposide has been researched along with echinomycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oka, H; Okada, H; Okura, A; Suda, H; Uemura, D; Yamada, A; Yoshinari, T | 1 |
| Blum, RH; Bonomi, P; Boucher, H; Chang, AY; Karp, DD; Kim, K; Stewart, JA | 1 |
1 trial(s) available for etoposide and echinomycin
| Article | Year |
|---|---|
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Echinomycin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Intercalating Agents; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Remission Induction; Survival Rate; Trimetrexate | 1998 |
1 other study(ies) available for etoposide and echinomycin
| Article | Year |
|---|---|
Inhibition of topoisomerase II by a novel antitumor cyclic depsipeptide, BE-22179.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; DNA Topoisomerases, Type I; Echinomycin; Etoposide; Leukemia L1210; Nucleic Acid Conformation; Peptides; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |